Evidence map›Paper›PMID 21998583›Full record

ArticlePLoS pathogens2011

Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response.

Diana S Smith, Kejun Guo, Bradley S Barrett, Karl J Heilman, Leonard H Evans, Kim J Hasenkrug, Warner C Greene, Mario L Santiago

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. APOBEC3 enzymes restrict marginal zone B cells.European journal of immunology · 2015
    Article
  17. Article
  18. Article
  19. Article
  20. Mouse knockout models for HIV-1 restriction factors.Cellular and molecular life sciences : CMLS · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Diana S SmithDepartment of Medicine, University of Colorado Denver, Aurora, Colorado, United States of America.
Kejun Guo
Bradley S Barrett
Karl J Heilman
Leonard H Evans
Kim J Hasenkrug
Warner C Greene
Mario L Santiago
University of Colorado Denver · USNational Institute of Allergy and Infectious Diseases · USGladstone Institutes · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Immunology And Pathology Of Acute Murine Leukemia Virus InfectionsZIAAI000753 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2022
$8.1M
Roles of Endogenous Retroviruses in Cancer and Auto-immune DiseasesZIAAI001103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI EVANS, LEONARD · 2009 to 2016
$3.1M
Innate Restriction Factor Modulation of Retrovirus-specific Humoral ImmunityR01AI090795 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2010 to 2013
$2.8M
Apobec3 and the Neutralizing Antibody Response Against Pathogenic RetrovirusesR56AI084123 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2009 to 2009
$658k
Intramural NIH HHSNIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI090795NIAID NIH HHS R56 AI084123
6 · The paper itself

Abstract

Members of the APOBEC3 family of deoxycytidine deaminases counteract a broad range of retroviruses in vitro through an indirect mechanism that requires virion incorporation and inhibition of reverse transcription and/or hypermutation of minus strand transcripts in the next target cell. The selective advantage to the host of this indirect restriction mechanism remains unclear, but valuable insights may be gained by studying APOBEC3 function in vivo. Apobec3 was previously shown to encode Rfv3, a classical resistance gene that controls the recovery of mice from pathogenic Friend retrovirus (FV) infection by promoting a more potent neutralizing antibody (NAb) response. The underlying mechanism does not involve a direct effect of Apobec3 on B cell function. Here we show that while Apobec3 decreased titers of infectious virus during acute FV infection, plasma viral RNA loads were maintained, indicating substantial release of noninfectious particles in vivo. The lack of plasma virion infectivity was associated with a significant post-entry block during early reverse transcription rather than G-to-A hypermutation. The Apobec3-dependent NAb response correlated with IgG binding titers against native, but not detergent-lysed virions. These findings indicate that innate Apobec3 restriction promotes NAb responses by maintaining high concentrations of virions with native B cell epitopes, but in the context of low virion infectivity. Finally, Apobec3 restriction was found to be saturable in vivo, since increasing FV inoculum doses resulted in decreased Apobec3 inhibition. By analogy, maximizing the release of noninfectious particles by modulating APOBEC3 expression may improve humoral immunity against pathogenic human retroviral infections.

Indexed as

Antibody FormationAnimalsAntibodies, NeutralizingAntiviral AgentsCytidine DeaminaseFriend murine leukemia virusMiceMice, Inbred BALB CMice, KnockoutPhenotypePlasmaPromoter Regions, GeneticReverse TranscriptionRNA, ViralSequence Analysis, RNAViral LoadAntibodies, NeutralizingAntiviral AgentsApobec3 protein, mouseCytidine DeaminaseRNA, Viral

Identifiers

PMID21998583
PMCPMC3188525
OpenAlexW1973325647

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.